ST. LOUIS — On a cloudy morning in Forest Park, families gathered not just to take steps together but to take them for each other. The Muscular Dystrophy Association's 2025 Muscle Walk on May 4 drew ...

Sarepta Therapeutics’ report of a second fatality this year in a patient dosed with its Duchenne muscular dystrophy gene therapy raised the prospect it might have to pull the product from the market.

Duchenne therapy may be evolving from slowing disease to reversing it—with RNA approaches offering the prospect of restoring function. Ongoing research will determine if these advances can deliver ...

April 2 (Reuters) - A small trial of U.S.-based AVI BioPharma Inc's experimental muscular dystrophy drug met its goal of increasing levels of a key protein, but did not demonstrate that the drug had ...